GUIDED THERAPEUTICS INC
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
GTHPStored price and day change unavailable
Contents
Unaudited Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||
|---|---|---|
| (unaudited, in thousands) | ||
| March 31, | December 31, | |
| 2025 | 2024 | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $115 | $388 |
| Accounts receivable, net of allowance for credit losses of $1 at March 31, 2025 and December 31, 2024 | 2 | 3 |
| Inventory, net of reserves of $818 at March 31, 2025 and December 31, 2024 | 633 | 633 |
| Other current assets | 61 | 173 |
| Total current assets | 811 | 1,197 |
| Non-Current Assets: | ||
| Property and equipment, net | 21 | 23 |
| Operating lease right-of-use asset, net of amortization | 118 | 141 |
| Other assets | 17 | 17 |
| Total non-current assets | 156 | 181 |
| TOTAL ASSETS | $967 | $1,378 |
| LIABILITIES AND STOCKHOLDERS DEFICIT | ||
| Current Liabilities: | ||
| Accounts payable | $2,152 | $2,094 |
| Accounts payable, related parties | 34 | 36 |
| Accrued liabilities | 1,062 | 1,011 |
| Deferred revenue | 670 | 849 |
| Current portion of lease liability | 110 | 106 |
| Short-term notes payable due to related parties | 24 | 70 |
| Current portion of long-term debt, related parties | 530 | 532 |
| Short-term notes payable | 48 | 92 |
| Short-term convertible notes, net of discounts | 73 | 117 |
| Short-term convertible debt in default | 1,130 | 1,130 |
| Derivative liability at fair value | 66 | 118 |
| Total current liabilities | 5,899 | 6,155 |
| Long-Term Liabilities | ||
| Long-term lease liability | 20 | 49 |
| Long-term notes payable | 41 | 47 |
| Long-term convertible debt | 35 | 14 |
| Long-term debt, related parties | - | 2 |
| Total long-term liabilities | 96 | 112 |
| Total liabilities | 5,995 | 6,267 |
| COMMITMENTS AND CONTINGENCIES (Note 6) | ||
| STOCKHOLDERS DEFICIT: | ||
|---|---|---|
| Series C convertible preferred stock, $0.001 par value; 9.0 shares authorized, nil and 0.3 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively. Liquidation preference of nil and $286 at March 31, 2025 and December 31, 2024, respectively. | - | 105 |
| Series C1 convertible preferred stock, $0.001 par value; 20.3 shares authorized, 0.4 and 1.0 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively. Liquidation preference of $374 and $1,049 at March 31, 2025 and December 31, 2024, respectively. | 61 | 170 |
| Series C2 convertible preferred stock, $0.001 par value; 5,000 shares authorized, nil and 2.7 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively. Liquidation preference of nil and $2,700 at March 31, 2025 and December 31, 2024, respectively. | - | 439 |
| Series D convertible preferred stock, $0.001 par value; 6.0 shares authorized, 0.1 and 0.4 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively. Liquidation preference of $88 and $438 at March 31, 2025 and December 31, 2024, respectively. | 32 | 159 |
| Series E convertible preferred stock, $0.001 par value; 5.0 shares authorized, 0.9 shares issued and outstanding as of March 31, 2025 and December 31, 2024. Liquidation preference of $883 at March 31, 2025 and December 31, 2024. | 834 | 834 |
| Series F convertible preferred stock, $0.001 par value; 1.5 shares authorized, 1.0 shares issued and outstanding as of March 31, 2025 and December 31, 2024. Liquidation preference of $981 at March 31, 2025 and December 31, 2024. | 817 | 817 |
| Series F-2 convertible preferred stock, $0.001 par value; 5.0 shares authorized, 0.5 shares issued and outstanding as of March 31, 2025 and December 31, 2024. Liquidation preference of $495 and $520 at March 31, 2025 and December 31, 2024, respectively. | 452 | 475 |
| Common stock, $0.001 par value; 500,000 shares authorized, 77,968 and 65,131 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively. | 3,464 | 3,452 |
| Additional paid-in capital | 143,616 | 142,501 |
| Treasury stock at cost | (132) | (132) |
| Accumulated deficit | (154,172) | (153,709) |
| Total stockholders deficit | (5,028) | (4,889) |
| TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT | $967 | $1,378 |
GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.